TESSA technology: a new paradigm in AAV manufacturing

Cell & Gene Therapy Insights 2020; 6(8), 1225

10.18609/cgti.2020.134

Published: 1 October 2020
FastFacts
Ryan Cawood

Watch the video or read the poster to learn:

  • Benefits and drawbacks of current AAV viral vector production methods
  • How Tetracycline Enabled Self Silencing Adenovirus (TESSA) allows efficient, scalable AAV manufacture
  • Results from studies comparing TESSA with conventional methods

About the speaker

Ryan Cawood founded Oxford Genetics in 2011, after earning a first class degree in genetics and a PhD from Oxford University. The idea behind the company was to simplify and standardise the process of DNA engineering using a proprietary DNA plasmid platform called SnapFast™ that allowed researchers – for the first time – to assemble complex sections of DNA as simply as ‘molecular Lego’. Ryan used his background in genetic engineering and virology to guide and grow the business through a series of strategic changes that explored how further development of the SnapFast™ platform through in house research and development could help overcome multiple challenges in the development of new biologics. This culminated in a rebrand to OXGENE in 2019, as the company redefined itself as a leading solutions provider, using a combination of proprietary technologies to address multiple pinch-points on the journey through design, discovery, development and manufacture of a novel biologic.




We hope you enjoyed this FastFacts video. You can also view the summary PDF here.


This article is part of the Scaling up/out: cost-effective and robust transitioning through the clinic to commercial manufacture spotlight